Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Google's proposed data center in orbit will face issues with space debris in an already crowded orbit - 2Israel reports first missile fire from Yemen since start of Iran war
- 3Vote in favor of your Favored kind of footwear
- 4Satellite data reveals a huge solar storm in 2024 shrank Earth's protective plasma shield
- 5Figure out How to Explore the Infotainment Framework in the Slam 1500.
- He made a name for himself posting thirst traps on TikTok. Now he's the star of a wildly popular rom-com.
- Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
- From Overpowered to Coordinated: Individual Accounts of Cleaning up
- Step by step instructions to Get a good deal on Your Rooftop Substitution Venture
- First foreign troop in new gang suppression force lands in Haiti to replace previous mission
- Extraordinary Shows to Long distance race on a Plane
- Israeli archaeologists launch project to trace origins of ancient pottery
- New studies of old dogs help scientists understand where they came from
- Malaysia To Revive Search for Missing Flight MH370
